



Lupin Manufacturing Solutions

CDMO + API Solutions

March 2025



We are Lupin Manufacturing Solutions

Lupin Manufacturing Solutions (LMS) provides insights, development and manufacturing services for all stages of drug substance development.

Our focus is cost effective supply of molecules with a range of synthetic complexity:

- Small molecules across all the value chain
- Highly potent compounds
- ADC linker-payload
- Peptides
- Fermentation semi-synthetics

LMS builds on the robust performance of its parent



FINANCIALS

\$2,300 Mn

Total Revenue From Operations

\$452 Mn

EBITDA



R&D

866

Active Patents Applications
as of March 2024

442

ANDAs and NDAs filed with
U.S. FDA as of March 2024



RANKINGS

3rd

In the U.S. (by prescriptions)

7th

In the Indian Pharma Market



PRODUCTS

25+

Robust Injectables Pipeline
for FY25

15+

Robust Pipelines of Respiratory
Products for FY25

27 Bn+

Formulation Units Sold Globally
(IQVIA MAT Mar 24 Standard Units)

1,420,000+

Patients Reached Through Patient
Education Programs

78,000+

HCPs Participated in Doctor
Education Programs

21% YoY

Reduction in Scope 1 and Scope 2
Emissions in FY24

Our Development and Manufacturing Network

Our world-class facilities ensure we deliver tailor-made solutions to our customers



Dabhasa 505

C F T M W

Large-scale cGMP manufacturing facilities and multi-purpose small-scale plants

Pune 215

C

Centre of Excellence development & cGMP clinical supply for range of modalities

Vizag 210

C F A M W

Large-scale cGMP manufacturing facilities including dedicated facility for potent molecules



Corporate Office: Mumbai

20



Business Development

● Employees

C GMP

F FDA inspected

T TGA inspected

M MFDS Inspected

F ANVISA Inspected

W WHO-CDSCO

LMS Overview

Enables innovative large pharma, mid-pharma and small pharma companies to develop the next generation of life-changing pharmaceuticals

- Leading developer and manufacturer of cost effective and complex Registered Starting Materials (RSM), Pharmaceutical Intermediates (PI) and Active Pharmaceutical Ingredients (API) for pharma customers
- Focused on cost effective supply of high-quality molecules with a range of synthetic complexity
- Operates across the drug substance value chain of the CDMO market serving two segments, Originators and Generics

Major
API Producer



3 Development
&
Manufacturing
Facilities

~1000 Global
Employees

>200
R&D Scientists

We work with Originators on their Drug Substance challenges

Operating across the complete lifecycle & the full value chain



LMS Executive Management Team

Deep industry experience across all functions and multiple modalities and geographies



Dr. Abdelaziz Toumi
CEO



Dr. Rakesh Ganorkar
CSO



Vijay Ghogare
COO



DVS Varma
CQO



Ajay Tiwari
CHRO



Alok Kumar
CFO



Akhil Varma
VP, Strategy &
Portfolio
Management

Driving functional excellence across commercial, development, operations, quality, strategy and human resources to ensure customer delight.

Experience across wide range of modalities from key players: Lonza, Catalent, Veranova, Cambrex, Biocon, Sandoz, Hikal, SAI Life Sciences

Technology Platform

Range of platforms to enable supply of cost-effective drug substance




Deep experience across the platform enables rapid development, scale up and validation

Learning over multiple projects enables most favorable cost of goods at commercial scale

Development Center



Labs	Number
Synthesis	7
Analytical	15
Fermentation Development	5
Enzyme Development	2
PECG	1
Containment Lab	1
Steroid & Hormones	1
Peptide Chemistry	2
Process Safety	1
High Pressure	1
Kilo Lab	1



R&D Services can be offered all through the spectrum of drug development

Development capability

Ability to deploy technology platform to address phase appropriate development & clinical needs



Pune

Development Facilities

- Development Labs and GMP Kilo Lab
- 75 FTEs for chemistry; 25 for biotechnology and 70 for analytical development
- Complete capability for optimization of solid form and product characterization
- Complete capability for chemical, biochemical & analytical development
- Hi-containment lab for handling upto OEL 0.1 µg/m³
- Peptide development lab (Synthesis & Purification)

Small-Scale Facilities

- 20L – 250L scale glass, steel and Hastelloy reactors (-50 °C to 180°C)
- Centrifuge, Nutsche, pressure filtration and milling, micronization, nano and micron filters

Capacity & capability for rapid development and deployment to clinical supply & technology transfer

Manufacturing capability

Ability to rapidly scale cost effective processes to address timely market access and commercial volumes



Vizag

HPAPI & Multi-purpose Full Scale Manufacturing

HPAPI:

- Fixed isolators & dedicated detoxification
- Glass, steel and Hastelloy reactors from 0.2M³ – 1M³ (-20°C to 150°C & pressure up to 4 Bar)
- Pressure filtration & drying, tray drying, sifting & milling

Multi-Purpose:

- Glass and Hastelloy reactors from 0.1M³ – 8M³ (-80°C to 150°C & pressure up to 10 Bar)
- Centrifuge, Nutsche, pressure filtration, milling & micronization
- Specialist unit operations - tangential flow filtration, wiped film evaporation & spray, fluidized bed & Nauta drying

Dabhasa

Multi-purpose Full Scale Manufacturing

- Glass and Hastelloy reactors from 0.25M³ – 10M³ (-20°C to 150°C & pressure up to 4 Bar)
- Hydrogenators 0.63M³ – 3M³, (up to 10 Bar)
- Specialist equipment for 200°C & 20 Bar operations
- Centrifuge & pressure filtration separation & drying, milling & micronization
- Specialist unit operations - lyophilization, nano filtration, wiped film evaporator, Nauta dryer and column chromatography

Wide range of process operating conditions and unit operations to address needs of cost-effective manufacture


Technology Transfer Teams for internal transfer or external receipt of processes for rapid demonstration and scale-up

Vizag HPAPI Capability

Commercial supply from 1Kg – 30 Kg scale for OEL of 0.05 µg/m³ or higher



Operations undertaken in Intermediates & Clean Room environments – dedicated detoxification area



The isolators in intermediate and clean area are designed for ISO Class 8 environment (Class 100,000)

Vizag capability on-line in June 2025 – additional existing asset to be brought on stream as needed

MSG L= Mild Steel Glass Lined; SS= Stainless Steel; HT= Hastelloy, ANFD= Agitated Nutsche Filter Dryer

VTD= Vacuum Tray Dryer (3 Kg = Tray capacity)

Non-contained
environments

Contained
environments

Highly Potent Active Pharmaceutical Ingredients (HPAPI)



Development & manufacturing at OEL of 0.05 µg/m³ (SafeBridge 3+) or higher

Lupin Manufacturing Solutions	1	2	3	4	5			6	
SafeBridge [®]	1	2	3	3+	4				
OEL (µg/m³)	1,000	500	100	10	1	0.6	0.1	0.03	0.01
Max. Dosage (µg/day)	10,000	5,000	1,000	100	10	6	1	0.3	0.1

SafeBridge [®]			Lupin Manufacturing Solutions		
Max. Dosage (µg/day)	OEL Range (µg/m³)	OEB (Occupational Exposure Band)		Max. Dosage (µg/day)	OEL Range (µg/m³)
>5,000	>500	1	1	>10,000	>1,000
100 – 5,000	10 – 500	2	2	1,000 – 10,000	100 – 1,000
			3	100 – 1,000	10 – 100
6 – 100	0.6 – 10	3	4	10 – 100	1 – 10
0.3 – 6	0.03 – 0.6	3+	5	0.1 – 10	0.1 – 1
<0.3	<0.03	4	6	<0.1	<0.1

Summary of SafeBridge and LMS' HPAPI banding

Complete range of capability from development through commercial supply for OEL of 0.05 µg/m³ or higher

Pune Development

- Process development
- Non-GMP for toxicology & formulation development
- Synthesis, filtration, drying & finishing
- Fixed isolators & dedicated detoxification

Vizag Kg Labs

- 0.5 Kg scale demonstration
- cGMP for clinical & commercial supply
- Isolators for operation at 3L scale
- Dedicated lab for potent material analysis
- Quality Control lab for in process control and product release

Vizag Production¹

- 1 Kg – 30 Kg scale
- cGMP for commercial supply
- 0.2M³ – 2M³ reactors with MSGL², SS³ and Hastelloy
- Isolators for all dispensing, charging, discharging, sampling, filtration, drying, milling & micronization.
- Dedicated area for detoxification / decontamination

Wide range of process operating conditions and unit operations to address needs of cost-effective manufacture

¹ Vizag capability on-line in June 2025; ² Mild Steel Glass Lined; ³ Stainless Steel

HPAPI Manufacturing capability

Ability to rapidly scale Hi-potent molecules at Vizag



INTERMEDIATE AREA



PP AREA

Quality, Compliance and Regulatory Affairs

More than 80 DMFs filed in 10+ countries



- FDA / TGA / ANVISA / MFDS / CDSCO / WHO approved sites in India
- Regulatory Affairs support and submissions
- Active dossiers in China, South Korea
- Validated computer systems for Quality Systems Management
- Regularly audited by our global customer base
- Exemplary audit history

Dabhasa

FDA, 2024 – NAI
WHO-CDSCO, 2023 – Certificate Issued
TGA, 2020 – Certificate Issued

Vizag

FDA, 2023 – NAI
WHO, 2023 – Certificate Issued
ANVISA, 2022 – Certificate Issued

Commercial Generic API Portfolio

>30 years of combined experience in compliant, cost-effective manufacture at Dabhasa and Vizag sites



> 40 commercial APIs addressing major diseases

Haematology

Infectious
Disease

Neurology

Psychiatry

Renal

Respiratory

Enabling affordable medicines for critical treatments

Regulatory Affairs ensures access
to all key markets

Robust supply chain & systems
drives on time deliver

Excellence in quality secures
fully compliant product

Reliable supplier of high quality, cost-effective drug substance and providing access to key markets

ESG: Embedding Sustainability across Manufacturing

LMS fully integrated in the group program, enhancing Lupin's ESG score



100% sites in India successfully covered with ISO 14001 and 45001 certification.



Strong focus on Environment at Manufacturing locations (Decarbonization) – investments on Renewable Energy, Alternate Fuels, Energy Efficiency, Waste Management and Water Recycling.




Integrating ethical practices within our supply chain, emphasizing fair labor practices and responsible sourcing – ESG Assessment for suppliers.



Adopting Green Chemistry Principles – By bringing down product carbon and water footprints, reducing use of hazardous chemicals and solvents and replacing them with renewable green solvents and feedstocks.

Strong performance Year on Year in ESG Ratings

S&P Global ESG Score



B Climate **C** Water

Lupin Manufacturing Solutions

Your partner for high quality & cost-effective development and manufacturing of drug substance



Development

Pune development & clinical supply facility

- Capacity & capability to achieve timely, phase appropriate process development for optimal manufacturing process

Technology Transfer

Dabhasa and Vizag demonstration & scale-up facilities

- Experienced team for robust transfer & rapid deployment of processes

Manufacturing Across Value Chain

Dabhasa and Vizag manufacturing facilities

- Ability to scale manufacture of starting materials, intermediates and active ingredients through validation into supply

Quality, Regulatory & Compliance

Implemented across all GMP activities at all locations

- Robust quality & compliance systems for confidence in supply supported by global regulatory filings

Supply of Generic Active Ingredients

Dabhasa and Vizag manufacturing facilities

- Reliable supplier of high quality, cost-effective drug substance and providing access to key markets

Environmental, Social & Governance

Lupin Group initiatives fully integrated into LMS

- Strong & demonstrable commitment to ESG principles with year-on-year improvements across all parameters

Executed with strict maintenance of confidential information and project management excellence

Fast Track to toxicology & clinical API supply



Well defined, confident and cost-effective approach for fast tracking early lifecycle entities

	Features	Benefit for Customers	Value
Pricing	Fixed fee/ FTE model with clear SoW	Clarity on deliverables, timeline & cost (what, when & how much) Ensures costs remain within budget	Clarity, confidence, cost-effectiveness
Solid Form	Flexible solid form exploration as needed, and proactive selection of salt/co-crystal in early development Flag IP opportunities for life-cycle extension	Most viable option in line with formulation Avoid changes in later clinical development	Smooth transition into and through clinical trials Extend market position, revenue / profit
Chemical Development	Expedited familiarization run through & reduction to practice processes Optimized scale-up in Kg Lab	Fast delivery of toxicology or clinical product	Lightspeed deliveries
Analytical Development	Pre-defined SoWs: GMP release; utilize client methods; develop in-house methods; method validation	Customized offer that aligns with program needs and budget	Cost-effectiveness, Speed
Production	Up front clarity on QA standards & expectations Pre-determined in-process controls	Deliverables meet expectations Avoid extra costs associated with rework Agility during execution	Clarity, confidence, cost-effectiveness Speed to market

✓ Offerings as per the Voice of Customer

✓ Cost-effective & Lightspeed Deliveries

A large, stylized green lupine flower graphic on the left side of the slide, composed of four rounded petals.

Thank You



lupin.com



x.com/LupinGlobal



linkedin.com/company/lupin



youtube.com/c/LupinGlobal



facebook.com/LupinWorld/